Compare TG & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TG | BIOA |
|---|---|---|
| Founded | 1988 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 239.6M | 255.6M |
| IPO Year | 1994 | 2024 |
| Metric | TG | BIOA |
|---|---|---|
| Price | $5.58 | $5.44 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $28.89 |
| AVG Volume (30 Days) | 273.7K | ★ 739.5K |
| Earning Date | 11-06-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 151.06 | 66.21 |
| EPS | ★ 0.26 | N/A |
| Revenue | ★ $800,821,000.00 | $8,995,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $83.62 |
| P/E Ratio | $21.79 | ★ N/A |
| Revenue Growth | ★ 8.29 | N/A |
| 52 Week Low | $5.26 | $4.81 |
| 52 Week High | $10.53 | $25.96 |
| Indicator | TG | BIOA |
|---|---|---|
| Relative Strength Index (RSI) | 28.75 | 39.92 |
| Support Level | N/A | $4.81 |
| Resistance Level | $8.15 | $6.30 |
| Average True Range (ATR) | 0.42 | 0.47 |
| MACD | -0.19 | 0.10 |
| Stochastic Oscillator | 12.52 | 35.87 |
Tredegar Corp is engaged in the manufacture of aluminum extrusions and polyethylene and polypropylene plastic films. It produces surface protection films, packaging films and films for other markets. The company continues to have two reportable segments: Aluminum Extrusions and High Performance Films. The majority of the revenue is derived form the Aluminum Extrusions segment which produces high-quality, soft and medium strength alloyed aluminum extrusions, custom fabricated and finished, for the building and construction, automotive and transportation, consumer durables goods, machinery and equipment, electrical and renewable energy, and distribution markets.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the identification of targets based on insights into molecular changes that drive aging. The Company operates and manages its business as one reportable and operating segment, which is the business of extending healthy human life by targeting molecular causes of aging.